Newsletter | October 16, 2026

10.16.26 -- Turning Data Into Decisions: Smarter Tools For Faster, Stronger Trials

SPONSOR

Webinar: Closing the Gap Between Biomarker Data and Clinical Proof-of-Mechanism in Neurodegenerative Disease

How can sponsors determine whether a therapy reaches the CNS, engages its target and produces meaningful biological effects? In this webinar, experts from CHDR and Ardena will share insights from a 15-year partnership, using GCase and lipid biomarker case studies to explore integrated clinical and bioanalytical strategies that support target engagement, proof-of-mechanism and early development decisions. Click here to learn more.

CLINICAL DATA MANAGEMENT & ANALYTICS

What Ecological Momentary Assessment Taught Us About Real-World Hearing Outcomes

Guest Column | By Megan Quilter, Au.D., and Nikki Mutter, Au.D.

Ecological momentary assessment (EMA) reveals how people experience hearing challenges beyond the clinic. Here, researchers highlight its relevance in designing real-world hearing studies.

Harness R Shiny Dashboards For Programming And Data Visualization

Article | By Roshan Stanly, Worldwide Flex

Empower your teams to move beyond static reports by leveraging R Shiny to transform data into interactive, real-time insights that drive smarter, faster decisions.

7 Silent Quality-Killers Of Clinical Trial Success

E-Book | Medidata, a Dassault Systemes company

Investigate seven hidden risks that quietly erode trial quality over time. Learn the early warning signs and how to catch and fix them before they escalate.

Accelerating Chronic Disease Clinical Study Reports With AI

White Paper | By Maria Hopfgarten, PPD Clinical Research Business of Thermo Fisher Scientific

AI-enabled medical writing can cut clinical study report timelines by up to 70%, helping teams manage growing chronic disease trial documentation without sacrificing quality or oversight.

Own Your Data, Accelerate Your Cure

Article | Castor

Move from passive donor to active innovator. Explore how patient communities are building their own research infrastructure and using AI to bypass traditional barriers to drug development.

TRIAL MONITORING

Your Company Needs Compliance Expertise — But When And From Whom?

Guest Column | By Adam Pajakowski, Crowe Advisory LLC

When should a biotech formalize compliance? Learn how risk, funding, clinical activity, and commercialization shape the right expertise and structure.

Connect With Clinical Leader: